SmithKline Beecham millionaires
SB Chairman Jan Leschly tells Wharton New Ventures meeting in Philadelphia April 16 that "we have more than 400 millionaires in our company" based on the fast run-up in the value of employee stock options. Leschly credited a four-year increase in SB's market cap from $12 bil. to $71 bil. and its effect on employee wealth with helping to staunch a management brain drain to start-up ventures. SB lost the number three member of its top management team, Pharmaceutical President Jerry Karabelas, to Novartis in late 1997
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth